Greg Perry Joins International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as new Assistant Director General
Geneva, 15th December 2017 – IFPMA, the global research-based biopharmaceutical industry association, today announced the appointment of Greg Perry as its new Assistant Director General (ADG). He will join IFPMA in mid-February 2018, and will have responsibility for IFPMA’s external outreach and stakeholder engagement in global health topics including innovation, access, and the international regulatory environment.
Greg Perry will join the re-vamped IFPMA leadership team of Thomas Cueni, who took over as Director General in February 2017 and, will work in tandem with Fumie Griego, who joined IFPMA in May as Assistant Director General with focus on value and access, vaccines, anti-microbial-resistance and ethics and business integrity. Greg Perry will bring with him more than 20 years’ leadership and advocacy experience in the public healthcare arena, most recently as Executive Director of the Medicines Patent Pool, in Geneva.
“I am very pleased to have someone with such depth of experience and recognized track record joining our leadership. Greg has proven capabilities on a broad range of issues and will help us to cross bridges and reach out to multiple stakeholders equally interested to drive global health progress for the benefit of patients.” said Thomas Cueni, IFPMA Director General.
“I will be joining IFPMA at an exciting time – where the role of the of the private sector as a major player in achieving universal healthcare is now regarded as essential. I have worked in a range of roles in the healthcare arena during the course of my career, but universal health care has been at the core of all of them. I very much look forward to joining the strengthened IFPMA leadership team and bringing solutions from another perspective,” commented Greg Perry.
Prior to his role as Executive Director of the Medicines Patent Pool, which he joined in 2013, Greg Perry was Director General of the European Generic Medicines Association (1999 -2013) in Brussels. Previously he worked as a partner in a UK public affairs company as a European Union policy advisor to corporate and non-governmental organisations, and before that as a Parliamentary Advisor to Members of the European Parliament.
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
For further information, please contact:
Helen Gallagher, email: firstname.lastname@example.org Tel: +41 22 338 32 19.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.Learn more
Media ContactElliot Dunster email@example.com